Technology

Heracles Pharmaceuticals has exclusive rights in the field of smoking cessation to 22nd Century’s extensive patent portfolio, which relates primarily to decreasing and increasing the expression of key genes and transcription factors responsible for the production of nicotine (and other nicotinic alkaloids) in the tobacco plant (depicted in blue in the above diagram) and the finished tobacco and products produced therefrom.

Model of the Nicotine Biosynthetic Pathway

 Technology